Thomas E. Malcolm, PhD

Thomas E. Malcolm provides advice on Gene Editing, Cell Therapy and Infectious Disease to FPG with respect to clinical and scientific matters related to current and prospective clients.

Dr. Malcolm currently serves as President and Chief Scientific and Innovations Officer of CaraVan Biologix, a company that he founded that is developing a novel technology to resolve the challenges associated in treating solid tumor cancers with CAR-T cell therapies as well as the delivery of gene editors to treat hereditary and infectious diseases. Dr. Malcolm also serves as the Co-Founder, COO and Board Member for Kermode Biotechnologies, (treating/protecting livestock from African Swine Fever Virus and Swine Influenza).

Thomas is a member of the SAB [i] for Cila Therapeutics (inhaled therapies for Primary Ciliary Dyskinesia and for late stage Sars-Cov-2 hydrofluidic lung infections), and [ii] for BioMark Diagnostics (metabolomic diagnostics).

Dr. Malcolm has deep expertise in CRISPR gene editing for human viral infectious diseases HIV, HBV, and HSV, chimeric antibody receptor therapeutics, animal viruses, oncology, gene editing delivery and targeting, and translational science into commercial products. Thomas has advised Aridis Pharmaceuticals (CRISPR-based antibody vaccines.

Dr. Malcolm has published his work on viruses and cancers. He is also a co-inventor on numerous patents. Thomas earned his Ph.D. in Biochemistry and Molecular Biology from the University of British Columbia, Vancouver, Canada and worked as a postdoctoral fellow at Sloan Kettering Memorial Cancer Center and Mount Sinai School of Medicine in New York.